Shari S Rogal1, Klaus Bielefeldt2, Ajay D Wasan3, Francis E Lotrich4, Susan Zickmund5, Eva Szigethy4, Andrea F DiMartini4. 1. Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh, Pittsburgh, Pennsylvania; Center for Health Equity Research and Promotion, Veterans Affairs Healthcare System, Pittsburgh, Pennsylvania. Electronic address: shari.rogal@gmail.com. 2. Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh, Pittsburgh, Pennsylvania. 3. Department of Anesthesia, University of Pittsburgh, Pittsburgh, Pennsylvania. 4. Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania. 5. Center for Health Equity Research and Promotion, Veterans Affairs Healthcare System, Pittsburgh, Pennsylvania; Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND & AIMS: Cirrhosis is associated with significant pain and disability, the etiologies of which are poorly understood. We investigated whether the pain and disability in patients with cirrhosis are associated with systemic inflammation and psychiatric symptoms. METHODS: In a prospective study, we recruited 193 patients with cirrhosis caused by hepatitis C virus infection, nonalcoholic steatohepatitis, or alcohol from the hepatology clinic at the University of Pittsburgh. Patients were assessed using the McGill Pain Questionnaire, the Hospital Anxiety and Depression Scale, the Pittsburgh Sleep Quality Index, and the Pain Disability Index. Serum samples were collected and markers of inflammation were measured using standardized Luminex assays (Milipore, St. Charles, MO). We evaluated factors associated with pain, pain-related disability, and chronic opioid use by using multivariable regression models. RESULTS: Pain was reported by 79% of patients, pain-related disability was reported by 75%, and depression and/or anxiety was reported by 47%; the average Model for End-Stage Liver Disease score was 12 ± 5. Serum samples from 58% percent of patients had increased levels of C-reactive protein. Opioids were prescribed for 30% of patients with pain. In multivariate analysis, factors significantly associated with pain included younger age (odds ratio [OR]/y, 0.93; 95% confidence interval [CI], 0.90-0.99), serum level of interleukin 6 (OR per pg/L, 1.63; 95% CI, 1.09-2.58), Hospital Anxiety and Depression Scale score (OR/point, 1.14; 95% CI, 1.07-1.24), and etiology (hepatitis C virus infection vs alcohol: OR, 3.70; 95% CI, 1.27-11.11). Disability scores were related significantly to psychiatric symptoms (incidence rate ratio [IRR]/point, 1.04; 95% CI, 1.02-1.05), prescription opioid use (IRR, 1.49; 95% CI, 1.14-1.94), Model for End-Stage Liver Disease score (IRR/point, 1.02; 95% CI, 1.0001-1.05), level of C-reactive protein (IRR per mg/dL, 1.13; 95% CI, 1.02-1.24), and pain severity (IRR/point, 1.19; 95% CI, 1.08-1.32). CONCLUSIONS: Pain and disability are common among patients with cirrhosis, and are associated with inflammation, psychiatric symptoms, and opioid use, which potentially are modifiable. Although opioids are used commonly to treat pain, psychiatric symptoms and inflammation also might be treatment targets in this population. Published by Elsevier Inc.
BACKGROUND & AIMS:Cirrhosis is associated with significant pain and disability, the etiologies of which are poorly understood. We investigated whether the pain and disability in patients with cirrhosis are associated with systemic inflammation and psychiatric symptoms. METHODS: In a prospective study, we recruited 193 patients with cirrhosis caused by hepatitis C virus infection, nonalcoholic steatohepatitis, or alcohol from the hepatology clinic at the University of Pittsburgh. Patients were assessed using the McGill Pain Questionnaire, the Hospital Anxiety and Depression Scale, the Pittsburgh Sleep Quality Index, and the PainDisability Index. Serum samples were collected and markers of inflammation were measured using standardized Luminex assays (Milipore, St. Charles, MO). We evaluated factors associated with pain, pain-related disability, and chronic opioid use by using multivariable regression models. RESULTS:Pain was reported by 79% of patients, pain-related disability was reported by 75%, and depression and/or anxiety was reported by 47%; the average Model for End-Stage Liver Disease score was 12 ± 5. Serum samples from 58% percent of patients had increased levels of C-reactive protein. Opioids were prescribed for 30% of patients with pain. In multivariate analysis, factors significantly associated with pain included younger age (odds ratio [OR]/y, 0.93; 95% confidence interval [CI], 0.90-0.99), serum level of interleukin 6 (OR per pg/L, 1.63; 95% CI, 1.09-2.58), Hospital Anxiety and Depression Scale score (OR/point, 1.14; 95% CI, 1.07-1.24), and etiology (hepatitis C virus infection vs alcohol: OR, 3.70; 95% CI, 1.27-11.11). Disability scores were related significantly to psychiatric symptoms (incidence rate ratio [IRR]/point, 1.04; 95% CI, 1.02-1.05), prescription opioid use (IRR, 1.49; 95% CI, 1.14-1.94), Model for End-Stage Liver Disease score (IRR/point, 1.02; 95% CI, 1.0001-1.05), level of C-reactive protein (IRR per mg/dL, 1.13; 95% CI, 1.02-1.24), and pain severity (IRR/point, 1.19; 95% CI, 1.08-1.32). CONCLUSIONS:Pain and disability are common among patients with cirrhosis, and are associated with inflammation, psychiatric symptoms, and opioid use, which potentially are modifiable. Although opioids are used commonly to treat pain, psychiatric symptoms and inflammation also might be treatment targets in this population. Published by Elsevier Inc.
Authors: Adam H Crighton; Dustin B Wygant; Kathryn C Applegate; Robert L Umlauf; Robert P Granacher Journal: Spine J Date: 2014-04-24 Impact factor: 4.166
Authors: Laura E Targownik; Zoann Nugent; Harminder Singh; Shawn Bugden; Charles N Bernstein Journal: Am J Gastroenterol Date: 2014-09-02 Impact factor: 10.864
Authors: Signe Wiese; Christian Mortensen; Jens P Gøtze; Erik Christensen; Ove Andersen; Flemming Bendtsen; Søren Møller Journal: Liver Int Date: 2014-01-07 Impact factor: 5.828
Authors: S J Sukoff Rizzo; S J Neal; Z A Hughes; M Beyna; S Rosenzweig-Lipson; S J Moss; N J Brandon Journal: Transl Psychiatry Date: 2012-12-04 Impact factor: 6.222
Authors: Shari S Rogal; Klaus Bielefeldt; Ajay D Wasan; Eva Szigethy; Francis Lotrich; Andrea F DiMartini Journal: Dig Dis Sci Date: 2014-11-30 Impact factor: 3.199
Authors: Jessica B Rubin; Jennifer C Lai; Amy M Shui; Samuel F Hohmann; Andrew Auerbach Journal: J Clin Gastroenterol Date: 2021-10-14 Impact factor: 3.062
Authors: Shari S Rogal; Matthew J Chinman; William DeMonte; Sandra Gibson; Stephanie Hoyt-Trapp; Gloria J Klima; Naudia L Jonassaint; Jane M Liebschutz; Kevin L Kraemer; Jessica Merlin Journal: Dig Dis Sci Date: 2022-02-11 Impact factor: 3.487
Authors: Andrew M Moon; Yue Jiang; Shari S Rogal; Elliot B Tapper; Sarah R Lieber; A Sidney Barritt Journal: Aliment Pharmacol Ther Date: 2020-01-21 Impact factor: 8.171
Authors: Shari S Rogal; Lauren A Beste; Ada Youk; Michael J Fine; Bryan Ketterer; Hongwei Zhang; Steven Leipertz; Maggie Chartier; Chester B Good; Kevin L Kraemer; Matthew Chinman; Timothy Morgan; Walid F Gellad Journal: Clin Gastroenterol Hepatol Date: 2018-10-17 Impact factor: 11.382
Authors: Shari S Rogal; Viyan Udawatta; Imo Akpan; Akshata Moghe; Alexis Chidi; Amit Shetty; Eva Szigethy; Klaus Bielefeldt; Andrea DiMartini Journal: PLoS One Date: 2017-11-17 Impact factor: 3.240
Authors: Andrew M Moon; Stephanie E Watkins; Anna S Lok; Roberto J Firpi-Morell; Huy Ngoc Trinh; Justin T Kupec; Cheryl Schoen; Brent A Neuschwander-Tetri; A Sidney Barritt Journal: Dig Dis Date: 2020-08-24 Impact factor: 2.404
Authors: Shari S Rogal; Gautham Mankaney; Viyan Udawatta; Matthew Chinman; Chester B Good; Susan Zickmund; Klaus Bielefeldt; Alexis Chidi; Naudia Jonassaint; Alison Jazwinski; Obaid Shaikh; Christopher Hughes; Paulo Fontes; Abhinav Humar; Andrea DiMartini Journal: PLoS One Date: 2016-11-07 Impact factor: 3.240